
Cracking the Ceiling
You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media.
For decades, gender parity in the workplace has been the subject of discussion, debate, and data. But despite years of targeted initiatives, executive pledges, and shifting public discourse, women remain underrepresented in senior roles across most industries - particularly in science and technology. One executive who has seen both the limitations and the potential of change from inside the C-suite is Tara McGeehan, President of CGI UK and Australia, a London based global IT and business consulting services firm.
"Throughout my career, I have learnt that as women, we often subconsciously put limitations on ourselves for a variety of reasons," she says. "I have also learnt that sometimes limitations are put upon us outside of our comprehension or ability to control." These barriers - both internal and systemic - remain a defining feature of the female professional experience. Yet McGeehan argues that meaningful progress begins with the choices made at the very outset of a woman's career, specifically, where and with whom she chooses to work.
"For women looking to start a career, it is important to work for a company that emulates and reflects your values," she advises. "Does it already employ role models you can look up to and learn from? Will it inspire you? Can you see yourself thriving and developing in your career there?"
McGeehan advocates for a level of scrutiny on employers that is often reserved for applicants. In an increasingly talent-led labour market, she believes candidates should feel empowered to ask hard questions. "Ask yourself these questions or better still, ask them at the interview stage and see if it's the right fit for you. You want to work in a comfortable, supportive, and inclusive environment that supports you in your growth and success."
The ability to thrive in such an environment, she notes, is also tied to confidence and communication. Speaking up, particularly early in one's career, can be a challenge. But for McGeehan, it is essential. "Once you have secured your first role, I'd encourage you to share your thoughts and ideas. Diverse talent creates diverse ideas. This, in turn, pushes boundaries and innovation."
Innovation, she suggests, is not the product of a singular vision, but of collective input from across levels and backgrounds. "It's important to have strong female voices across the whole business, be it those in leadership positions or those in their first professional role."
Despite improvements in representation, McGeehan remains clear-eyed about the distance still to go. "There's still a long way to go in tackling the glass ceiling, and so none of us, regardless of our role, can afford to let up in our efforts to make our industry as diverse, equitable, and inclusive as it absolutely must be."
That sense of shared responsibility - at all levels - is a consistent theme in her commentary. While individual advancement is important, collective advocacy remains central to progress. So too does ambition, often viewed with discomfort or suspicion when expressed by women in the workplace. McGeehan is unequivocal: such ambition is not only acceptable, it is necessary.
"My final piece of advice is that it's okay to aspire to a successful career as a woman," she says. "If you have the ambition and the drive, and are working with a company that embraces this, there's no reason why you shouldn't achieve it."
Her words suggest a quiet but resolute optimism: that change is possible, but not inevitable. It must be built - consciously, collaboratively, and continuously.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
33 minutes ago
- Yahoo
Car dealers halt sales of two second-hand models amid 'stop-drive' warning
Car dealers have been told to halt sales of second-hand Citroens amid replacements to potentially dangerous airbags. The warning was extended after the French manufacturer's parent company Stellantis issued a 'stop-drive' notice to certain Citroen models in June. It comes after a woman sustained fatal injuries caused by an airbag in a 2014 Citroen C3 in Reims, France, last year. Now, second-hand Citroens are also being included in the warning amid thousands still being listed for sale across the UK, according to This is Money. 'Buyers could have been driving away in potentially dangerous motors while also invalidating their insurance,' an article states. Since then, a team of motor trade lawyers have now issued a nationwide warning to used car dealers to suspend sales of vehicles in stock What Citroens are being recalled? The vehicles affected are second-generation Citroen C3s produced from 2009 to 2016 and first-generation DS3s manufactured from 2016 to 2019. As a result, around 82,000 C3 and DS3 models have been removed from the road across France. What is the recall on the Citroen C3 2025? The vehicles use Takata airbag systems, which could be faulty. However, Stellantis UK said that there were no reported incidents of faults in the UK, but it has decided to take action regardless. The car manufacturer in a recent statement said: 'Stellantis UK is mobilising its full network of suppliers, retailers and manufacturing plant to support this action to ensure the fastest, safest and most convenient solution for each customer. 'Stellantis remains fully committed to acting swiftly, transparently, and responsibly in addressing this issue.' Owners have been told to book their vehicles in to be rectified as early as possible and to not drive them in the meantime. However, a study by Which? revealed that hundreds of these cars were listed for sale on major used vehicle websites with no information that the manufacturer had issued a stop-drive notice. How do I check my Citroen recall? If you already own an affected Citroen, you should be contacted by letter, or you can check whether your car is affected by using the VIN check tool on Citroen's website. Recommended Reading: Citroen C3 drivers told 'stop driving' due to airbag fault How you could get a roadside fine amid new DVSA changes DVLA issues warning to anyone who passed their driving test before 2015 You will need the vehicle identification number (VIN). You can find this: at point 1 on your MOT certificate in part 4 (vehicle details) at point E in the vehicle's log book (V5C) A spokesperson from Stellantis said that they were 'working to maximise' the number of vehicles it can repair each day, with priority given to those with urgent needs.


CNN
an hour ago
- CNN
Trump meets with Ursula von der Leyen as US-EU trade deadline nears
President Donald Trump began talks Sunday in Turnberry, Scotland, with European Commission President Ursula von der Leyen, as Friday's deadline looms to reach a trade deal to avoid the 30% tariffs on European imports. 'We'll probably know in about an hour. Shouldn't take that long. It's, you know, it's complicated, but not really complicated when you get right down to it,' Trump said during the news conference. Trump reiterated that the likelihood of striking a deal with the EU is '50-50.' This is a developing story and will be updated.